Stammdaten
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Unternehmen & Branche
| Name | Galera Therapeutics, Inc. |
|---|---|
| Ticker | GRTX |
| CIK | 0001563577 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 7,6 Mio. USD |
| Beta | 1,78 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 149,049,000 | 0.64 | 7,196,000 | 3,974,000 | |
| 2025-09-30 | 10-Q | -1,388,000 | -0.01 | 5,002,000 | -149,222,000 | |
| 2025-06-30 | 10-Q | -1,075,000 | 0.00 | 6,048,000 | -147,945,000 | |
| 2025-03-31 | 10-Q | -1,592,000 | -0.01 | 7,661,000 | -147,227,000 | |
| 2024-12-31 | 10-K | -18,957,000 | -0.34 | 10,101,000 | -148,041,000 | |
| 2024-09-30 | 10-Q | -5,581,000 | -0.10 | 8,901,000 | -143,062,000 | |
| 2024-06-30 | 10-Q | -4,064,000 | -0.07 | 16,383,000 | -138,032,000 | |
| 2024-03-31 | 10-Q | -4,381,000 | -0.08 | 19,651,000 | -134,691,000 | |
| 2023-12-31 | 10-K | -59,082,000 | -1.33 | 26,141,000 | -131,185,000 | |
| 2023-09-30 | 10-Q | -15,073,000 | -0.33 | 37,779,000 | -126,553,000 | |
| 2023-06-30 | 10-Q | -20,712,000 | -0.48 | 48,276,000 | -114,999,000 | |
| 2023-03-31 | 10-Q | -17,710,000 | -0.50 | 59,714,000 | -97,613,000 | |
| 2022-12-31 | 10-K | -62,222,000 | 44,036,000 | -109,181,000 | ||
| 2022-09-30 | 10-Q | -16,033,000 | -0.60 | 50,713,000 | -97,502,000 | |
| 2022-06-30 | 10-Q | -14,558,000 | -0.54 | 61,078,000 | -83,246,000 | |
| 2022-03-31 | 10-Q | -15,443,000 | -0.58 | 71,099,000 | -70,471,000 | |
| 2021-12-31 | 10-K | -80,534,000 | 83,311,000 | -58,004,000 | ||
| 2021-09-30 | 10-Q | -22,626,000 | -0.86 | 98,765,000 | -43,167,000 | |
| 2021-06-30 | 10-Q | -22,386,000 | -0.88 | 115,269,000 | -25,517,000 | |
| 2021-03-31 | 10-Q | -18,715,000 | 70,486,000 | -10,573,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.